Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

TMO

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

TMO

AI Research Report

Powered by Claude

Ready to analyze TMO

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

C+
Stonvex Quant Grade
50.0/ 100
Rank-normalised composite of 6 factors, updated every 60 seconds.
Volume
C+
50 / 100

Today's volume vs prior session average.

Volatility
C+
50 / 100

Absolute daily price move vs peers.

News Flow
C+
50 / 100

24h article count relative to the universe.

Sentiment
C+
50 / 100

AI-classified polarity of recent news.

Dollar Flow
C+
50 / 100

Today's dollar turnover (volume × VWAP).

Relative Strength
C+
50 / 100

Signed daily return vs the rest of the universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Similar stocks

View all Healthcare →
LLY
Eli Lilly
$810.50
+2.30%
UNH
UnitedHealth
$485.20
-2.51%
NVO
Novo Nordisk
—
—
JNJ
Johnson & Johnson
—
—
WELL
Welltower
—
—
ABBV
AbbVie
—
—
Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

whgksdhr1111@naver.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

Analyst Consensus

Buy
Based on 35 analysts
Period: 2026-04-01
31 Buy (89%)4 Hold (11%)0 Sell (0%)
Rating Distribution
Strong Buy
11
Buy
20
Hold
4
Sell
0
Strong Sell
0
Trend
2026-04
31/4/0
2026-03
29/4/0
2026-02
27/6/0
2026-01
28/4/0
  • Yahoo·10h ago

    A Look At Thermo Fisher Scientific (TMO) Valuation After Recent Share Price Volatility

    Event context and recent performance snapshot Thermo Fisher Scientific (TMO) has attracted fresh attention after a period of mixed share performance, with a gain over the past month alongside a decline over the past 3 months and year to date. See our latest analysis for Thermo Fisher Scientific. Recent trading has been volatile, with a 10.74% 1 month share price return contrasting with a 15.29% 3 month share price decline, while the 1 year total shareholder return of 14.86% hints at...

  • Yahoo·1d ago

    Will Thermo Fisher (TMO) Beat Estimates Again in Its Next Earnings Report?

    Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • Yahoo·1d ago

    Small Molecule Innovator API CDMO Market Outlook, 2026-2033 - Lonza Group, Novo Holdings (Catalent) and Thermo Fisher Scientific Lead the Growing Industry

    With a focus on specialty medicines, growth is driven by pharmaceutical needs for cost-effective, efficient production and regulatory compliance via CDMOs Small Molecule Innovator API CDMO Market Small Molecule Innovator API CDMO Market Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report by Stage Type, Customer Type, Therapeutic Area, Region, and Segment Forecasts, 2026-2033" has been added to ResearchAndMarkets.com's offe

  • Yahoo·1d ago

    Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

    Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

  • Yahoo·1d ago

    Thermo Fisher Scientific’s PPD Clinical Research Business Collaborates with HealthVerity to Expand Real-World Data Capabilities

    WALTHAM, Mass., April 13, 2026--Thermo Fisher Scientific, the world leader in serving science, today announced a strategic data collaboration with HealthVerity, a leading real-world data (RWD) marketplace, to enhance data-driven clinical development and evidence generation for biopharma sponsors.

  • Yahoo·1d ago

    Allergy Diagnostic Market by Product & Service, Test Type, Allergen, End User - Global Forecast to 2031

    The allergy diagnostic market is set to surge, projected to reach USD 10.77 billion by 2030 from USD 6.80 billion in 2025, at a CAGR of 9.6%. Technological innovation in diagnostics, such as multiplex immunoassays and molecular allergology, drives this growth by enhancing test accuracy and efficiency. North America leads the market, supported by advanced healthcare infrastructure. Major players like Thermo Fisher Scientific Inc. and Siemens Healthineers AG dominate the competitive landscape. Thi

  • Yahoo·1d ago

    Cell Therapy Technology Market Research and Global Forecast Report 2025-2030: Rising Chronic Disease Burden and CRISPR-Driven Gene Editing Innovations Driving Growth

    The global cell therapy technologies market is set to grow from USD 4.41 billion in 2025 to USD 7.91 billion by 2030, achieving a CAGR of 12.4%. Key growth drivers include advancements in regenerative medicine, increasing chronic disease prevalence, robust R&D investments, and innovations in gene editing, particularly CRISPR. The T-cells segment is projected to lead with the highest CAGR, spurred by the success of CAR-T and TCR therapies. The US remains a dominant player in North America, benefi

  • Yahoo·2d ago

    Thermo Fisher PRECISE SG100K Partnership Puts Valuation And Growth In Focus

    Thermo Fisher Scientific (NYSE:TMO) has entered a collaboration with Singapore's PRECISE to support the large scale PRECISE SG100K biobank initiative. The company is supplying integrated multi platform proteomics capabilities, including Olink PEA and Orbitrap Astral mass spectrometry, alongside partners such as Seer and Novogene. The alliance is intended to support population scale precision medicine research and biomarker discovery across the Asia Pacific region. For investors tracking...

  • View all news →
📅 Earnings in 9d (Apr 23)
NASDAQAfter-hours
TMO
$528.54
$14.31 (+2.78%)
After-hrs · vs prev close $514.23
Open
$515.80
Prev close
$514.23
Day range
$514.00 – $530.00
52W range
— – —
Mkt cap
—
P/E
—
EPS
—
Beta
—
⚠️
Dilution risk detected

3 offering-related filings in the last 60 filings. Latest: 424B5 on 2026-02-10. View all →

Recent insider activity

View all →
  • 4PRIMARY DOCUMENT
    14d ago
  • 4PRIMARY DOCUMENT
    14d ago
  • 4PRIMARY DOCUMENT
    14d ago
  • 4PRIMARY DOCUMENT
    14d ago
  • 4PRIMARY DOCUMENT
    14d ago